Cancer Drug Resistance: Rationale for Drug Delivery Systems and Targeted Inhibition of HSP90 Family Proteins

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582577

Authors

Clelia Mathieu

Samir Messaoudi

Elias Fattal

Juliette Vergnaud-Gauduchon

Affiliations

Soon will be listed here.

Abstract

Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.

Citing Articles

The Interplay between Heat Shock Proteins and Cancer Pathogenesis: A Novel Strategy for Cancer Therapeutics.

Somu P, Mohanty S, Basavegowda N, Yadav A, Paul S, Baek K Cancers (Basel). 2024; 16(3).

PMID: 38339390 PMC: 10854888. DOI: 10.3390/cancers16030638.

Transcriptome reveals the role of the gene in mediating antibiotic resistance through cell envelope modulation in SCCF01.

Qin Z, Peng K, Feng Y, Wang Y, Huang B, Tian Z Front Microbiol. 2024; 14:1295065.

PMID: 38239724 PMC: 10794384. DOI: 10.3389/fmicb.2023.1295065.

Transcriptome Analysis Reveals the Involvement of Mitophagy and Peroxisome in the Resistance to QoIs in .

Sun B, Zhou R, Zhu G, Xie X, Chai A, Li L Microorganisms. 2023; 11(12).

PMID: 38137993 PMC: 10745780. DOI: 10.3390/microorganisms11122849.

Synergy of hypoxia relief and heat shock protein inhibition for phototherapy enhancement.

Zhang G, Cheng W, Du L, Xu C, Li J J Nanobiotechnology. 2021; 19(1):9.

PMID: 33407570 PMC: 7789325. DOI: 10.1186/s12951-020-00749-5.

References

Alshaer W, Hillaireau H, Vergnaud J, Mura S, Delomenie C, Sauvage F . Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J Control Release. 2017; 271:98-106. DOI: 10.1016/j.jconrel.2017.12.022. View

Yoo S, Kim H, Rho J, Jeong S, Yun J, Yun I . Targeted inhibition of mitochondrial Hsp90 induces mitochondrial elongation in Hep3B hepatocellular carcinoma cells undergoing apoptosis by increasing the ROS level. Int J Oncol. 2015; 47(5):1783-92. DOI: 10.3892/ijo.2015.3150. View

Khandelwal A, Crowley V, Blagg B . Resorcinol-Based Grp94-Selective Inhibitors. ACS Med Chem Lett. 2017; 8(10):1013-1018. PMC: 5641966. DOI: 10.1021/acsmedchemlett.7b00193. View

Ismail S, Alshaer W . Therapeutic aptamers in discovery, preclinical and clinical stages. Adv Drug Deliv Rev. 2018; 134:51-64. DOI: 10.1016/j.addr.2018.08.006. View

Stope M, Koensgen D, Burchardt M, Concin N, Zygmunt M, Mustea A . Jump in the fire--heat shock proteins and their impact on ovarian cancer therapy. Crit Rev Oncol Hematol. 2015; 97:152-6. DOI: 10.1016/j.critrevonc.2015.08.008. View

Dufay Wojcicki A, Hillaireau H, Leite Nascimento T, Arpicco S, Taverna M, Ribes S . Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor. J Control Release. 2012; 162(3):545-52. DOI: 10.1016/j.jconrel.2012.07.015. View

Masgras I, Sanchez-Martin C, Colombo G, Rasola A . The Chaperone TRAP1 As a Modulator of the Mitochondrial Adaptations in Cancer Cells. Front Oncol. 2017; 7:58. PMC: 5370238. DOI: 10.3389/fonc.2017.00058. View

Lou S, Zhao Z, Dezort M, Lohneis T, Zhang C . Multifunctional Nanosystem for Targeted and Controlled Delivery of Multiple Chemotherapeutic Agents for the Treatment of Drug-Resistant Breast Cancer. ACS Omega. 2018; 3(8):9210-9219. PMC: 6120734. DOI: 10.1021/acsomega.8b00949. View

Nussinov R, Tsai C, Jang H . A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. Trends Pharmacol Sci. 2017; 38(5):427-437. PMC: 5403593. DOI: 10.1016/j.tips.2017.02.001. View

10.

Audisio D, Messaoudi S, Cegielkowski L, Peyrat J, Brion J, Methy-Gonnot D . Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery. ChemMedChem. 2011; 6(5):804-15. DOI: 10.1002/cmdc.201000489. View

11.

RANDOW F, Seed B . Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat Cell Biol. 2001; 3(10):891-6. DOI: 10.1038/ncb1001-891. View

12.

Alshaer W, Hillaireau H, Fattal E . Aptamer-guided nanomedicines for anticancer drug delivery. Adv Drug Deliv Rev. 2018; 134:122-137. DOI: 10.1016/j.addr.2018.09.011. View

13.

Yan C, Oh J, Yoo S, Lee J, Yoon Y, Oh Y . The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis. Toxicol Appl Pharmacol. 2012; 266(1):9-18. DOI: 10.1016/j.taap.2012.11.001. View

14.

Jacobson C, Kopp N, Layer J, Redd R, Tschuri S, Haebe S . HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 2016; 128(21):2517-2526. DOI: 10.1182/blood-2016-04-711176. View

15.

Mishra S, Ghosh S, Stothert A, Dickey C, Blagg B . Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold. ACS Chem Biol. 2016; 12(1):244-253. PMC: 5568423. DOI: 10.1021/acschembio.6b00747. View

16.

Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J . Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev. 2017; 117(15):10043-10120. PMC: 5611849. DOI: 10.1021/acs.chemrev.7b00042. View

17.

Lee S, Cho H . Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer. Biomacromolecules. 2018; 20(2):835-845. DOI: 10.1021/acs.biomac.8b01449. View

18.

Mellatyar H, Talaei S, Pilehvar-Soltanahmadi Y, Barzegar A, Akbarzadeh A, Shahabi A . Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art. Biomed Pharmacother. 2018; 102:608-617. DOI: 10.1016/j.biopha.2018.03.102. View

19.

Kang B, Plescia J, Song H, Meli M, Colombo G, Beebe K . Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest. 2009; 119(3):454-64. PMC: 2648691. DOI: 10.1172/JCI37613. View

20.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View